Driven by robust outcome trials demonstrating that sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP1RA) reduce major adverse cardiovascular events, heart failure hospitalizations, and progression of kidney disease, international and national guidelines recommend prioritizing pharmacologic treatment with proven cardiovascular and renal benefits in people with type 2 diabetes (PwT2D) evolving towards organ protection as primary therapeutic target (1–4). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.